A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
0actual
Sites
50
Countries
Argentina, Canada, China +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study terminated for strategic business reasons
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-23 | actual | When the study began enrolling |
| Primary completion | 2025-06-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-10 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: Bimagrumab — also filed as LY3985863
- Drug: Tirzepatide — also filed as LY3298176
- Drug: Bimagrumab Placebo
- Drug: Tirzepatide Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change from Baseline in Body Weight
measured Baseline, Week 36
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed